节律制药

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $130 to $160
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Wolfe Research Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $150
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)
  TipRanks · 2026/9/16
• 评级变动
  Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $150
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $105 to $159
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/6/17
• 评级变动
  CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 评级变动
  BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• 评级变动
  CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $154
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $141
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  J.P. Morgan Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $146
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• Form 144 | Rhythm Pharmaceuticals(RYTM.US) Director Proposes to Sell 5.24 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $105 to $155
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $151
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155
  \u5e02\u573a\u8d44\u8baf · 2026/7/16

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。